Marilynn Larkin

A dietary intervention restored kidney function in animal studies and in a pilot study of patients with chronic kidney disease.

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a

Palliative care offered more than 3 months before death appears to decrease the aggressiveness of end-of-life care for patients with ovarian cancer.

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration during general anesthesia or deep sedation.

The search for a better biomarker than creatine for acute kidney injury (AKI) has been “ long and elusive .” However, could researchers be on the right path now?

An FDA label change and consensus guidance notwithstanding, endocrinologists seem to have made up their minds on how to handle patients on GLP-1s at high risk for aspiration.

The recent US Food and Drug Administration (FDA) clearance of two over-the-counter (OTC) continuous glucose monitors (CGMs) — Dexcom's Stelo and

Guidance from professional societies on how to handle the risk for pulmonary aspiration during general anesthesia or deep sedation for patients taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs) continues to evolve, as does the US Food and Drug Administration’s (FDA’s) labeling for the drugs. The changes can be challenging to keep up with, and endocrinologists seem to be making their own decisions based on clinical experience and their interpretations of the potential impact and value of the emerging information.

Close to half of US adults with diabetes used telehealth services in 2022 and generally reported care comparable with that of in-patient visits.

Amid substantially rising opioid-related deaths and other harms in Canada, the city of Calgary is grappling with the potential closure of the Sheldon Chumir supervised consumption site.